ImmunityBio gets UAE marketing authorization for ANKTIVA in bladder and lung cancers

ImmunityBio, Inc.

UAE approved ANKTIVA for BCG-unresponsive NMIBC (CIS and papillary) and metastatic NSCLC after checkpoint failure.
NMIBC CIS cohort (N=100): 71% complete response rate; median DoR 26.6 months, with responses beyond 54 months.
Papillary-only cohort (N=80): 12-month disease-free survival 58.2%; 83.1% cystectomy-free at 36 months.
NSCLC checkpoint-refractory (N=79): median OS 14.6 months; 16.2 months in patients with ALC ≥1,000.
Authorization expands ANKTIVA's global regulatory footprint to 34 countries; validity through July 2031.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.